The FDA has issued draft guidance to clarify how it reviews off-label communications for the products it regulates. ?
The agency said it would like to simultaneously give manufacturers flexibility to make medical claims while protecting the public from misleading or false information. ?
In a draft document the FDA submitted to the Federal Register, the agency recommends that “firms accurately characterize and contextualize the relevant information about the product, including by